http://clincancerres.aacrjournals.org/content/early/2016/12/04/1078-0432.CCR-15-1535.long
I don't recall seeing a mouse study this successful before. This study utilized the orthotopic, syngeneic GL-261 mouse glioma model. Triple combination of PD-1 antibody, TIM-3 antibody, and stereotactic radiosurgery led to 100% mouse survival at day 100, while all untreated control mice were dead by day 30. Furthermore, the "cured" mice were completely resistant to new tumor formation when re-challenged with glioma cells. I'll upload this study to the Library, in the Immunology and Immunotherapy folder, Checkpoint inhibitor subfolder.